

**Keywords:** octreotide LAR; neuroendocrine tumours; antiproliferative activity

# Predictive factors of antiproliferative activity of octreotide LAR as first-line therapy for advanced neuroendocrine tumours

Faidon-Marios Laskaratos<sup>\*1</sup>, Martin Walker<sup>2</sup>, Keval Naik<sup>1</sup>, Emmanouil Maragkoudakis<sup>1</sup>, Nikolaos Oikonomopoulos<sup>1</sup>, Lee Grant<sup>3</sup>, Tim Meyer<sup>1,4</sup>, Martyn Caplin<sup>1</sup> and Christos Toumpanakis<sup>1</sup>

<sup>1</sup>Centre for Gastroenterology, Neuroendocrine Tumour Unit, Centre for Gastroenterology, Royal Free Hospital NHS Foundation Trust, London NW3 2QG, UK; <sup>2</sup>Department of Infectious Disease Epidemiology, School of Public Health, Faculty of Medicine, Imperial College London, London SW7 2AZ, UK; <sup>3</sup>Department of Radiology, Royal Free Hospital NHS Foundation Trust, London NW3 2QG, UK and <sup>4</sup>UCL Cancer Institute, University College London, London WC1E 6DD, UK

**Background:** The antiproliferative activity of octreotide LAR in neuroendocrine tumours (NETs) has been demonstrated by small retrospective studies and confirmed by a prospective phase III trial (PROMID). However, there are limited data about the duration and predictors of response. The aim of our retrospective study was to determine the time to radiological progression (TTRP) of disease and the factors that were associated with better response.

**Methods:** A total of 254 treatment naïve patients with advanced NETs and positive somatostatin receptor scintigraphy were included. Mean follow-up period was 42 months.

**Results:** The location of primary was in the small bowel in 204, pancreas in 22, lungs in 14, rectum in 7 and unknown in 7 patients. Most tumours were well-differentiated, G1 (58%) and G2 (23%). The majority of patients commenced octreotide LAR due to functional symptoms (57%), radiological progression (10%) or in the presence of asymptomatic and stable disease on the basis of data from the PROMID trial (18.5%). Partial response occurred in 5%. For all patients, the median TTRP was 37 months (95% confidence interval, CI: 32–52 months). There was a statistically significant shorter TTRP in patients with pancreatic tumours, liver metastases and intermediate grade tumours. Extremely raised (> 10 times the upper limit of normal) baseline chromogranin A levels were associated with an unfavourable outcome. In contrast, male sex, carcinoid heart disease and initiation of treatment in the presence of stable disease were predictive of a better response. Age, extra-hepatic metastases, presence of mesenteric desmoplasia, previous resection and functional status of the primary tumour did not affect response.

**Conclusions:** The duration of the antiproliferative effect of octreotide LAR seems to be longer than previously reported. This study has identified several predictors of response in a large cohort of patients with NETs on somatostatin analogue therapy.

Neuroendocrine tumours (NETs) are rare neoplasms with an incidence between 2 and 9.3 per 100 000 persons per year (Ramage *et al*, 2012). They represent a heterogeneous group of neoplasms, arising from neuroendocrine cells derived from the diffuse endocrine system. They may be associated with a specific syndrome due to hormone hypersecretion, which differentiates 'functional' from 'non-functional' tumours.

Somatostatin analogues (SSA) are commonly used to treat symptoms associated with hormone hypersecretion and have a favourable safety profile. The antiproliferative activity of SSA in NETs has been recently confirmed in two randomised placebo-controlled trials (Rinke *et al*, 2009; Toumpanakis and Caplin, 2013; Caplin *et al*, 2014). The PROMID trial was a placebo-controlled, double-blind, randomised study assessing the effect of octreotide

\*Correspondence: Dr F-M Laskaratos; E-mail: flaskaratos@gmail.com

Received 30 July 2016; revised 8 September 2016; accepted 3 October 2016; published online 3 November 2016

© 2016 Cancer Research UK. All rights reserved 0007–0920/16

LAR on the control of tumour growth in patients with metastatic, well-differentiated midgut NETs. The study demonstrated that octreotide LAR significantly lengthened the time to tumour progression compared with placebo (median time to tumour progression 14.3 months vs 6 months, respectively; Rinke *et al*, 2009). More recently, another randomised, double-blind, placebo-controlled trial evaluated the effect of lanreotide in patients with metastatic, well- or moderately differentiated, non-functional enteropancreatic NETs (the CLARINET trial). This study showed that lanreotide was associated with a significantly prolonged progression-free survival compared with placebo (median progression-free survival not reached vs 18 months, respectively; Caplin *et al*, 2014).

However, there are limited data regarding the duration of response and factors predictive of tumour control in patients with NETs on SSA therapy. The aims of the present study were to determine the mean time to radiological progression (TTRP) of disease and factors affecting radiological response to SSA therapy in a large cohort of patients with NETs treated with octreotide LAR.

## MATERIALS AND METHODS

**Patients.** A total of 254 patients with NETs treated with octreotide LAR (as monotherapy) in our centre from 2001 to 2014, were included in this retrospective study. All patients had confirmed histopathological diagnosis. All patients were treatment-naïve, but primary tumour resection before somatostatin analogue therapy was not an exclusion criterion. In addition, all patients had a positive somatostatin receptor scintigraphy before commencement of octreotide LAR.

**Somatostatin analogue therapy.** All patients (who were somatostatin naïve) had an initial test dose of subcutaneous (s.c.) octreotide (50 µg). If no immediate adverse effect was noted, patients either had an initial 2-week course of s.c. octreotide (100/200 µg tds) and then were switched over to octreotide LAR or patients were given monthly octreotide LAR after no reaction to a single test dose of s.c. octreotide. The initial dose of octreotide LAR was 20 mg/28 days in 198 patients and 30 mg/28 days in 56 patients.

**Study design.** A retrospective review of patient electronic records was performed. Data collected included patient demographics (age, sex), data on the characteristics of treatment with octreotide LAR (dose, indication), tumour characteristics (location of primary, functional status, grade, presence of carcinoid heart disease and mesenteric desmoplasia, presence of liver or extra-hepatic metastases, extent of liver involvement, resection of primary and TTRP), and biochemical data (baseline serum chromogranin A (CgA)).

NET tumours were retrospectively classified and graded according to WHO 2010 (Bosman *et al*, 2010). Tumours were graded into three levels based on tumour cell proliferation: G1: mitotic count <2 per 10 high-power fields and/or Ki67 ≤2%; G2: mitotic count 2–20 per 10 high-power fields and/or Ki67 3–20%; G3: mitotic count >20 per 10 high-power fields and/or Ki67 ≥20% (Rindi *et al*, 2007).

Extent of liver involvement (0: absence of liver metastases, 1: volume of liver metastases affecting <25% of hepatic parenchyma, 2: volume of liver metastases affecting 25–50% of hepatic parenchyma, 3: volume of liver metastases affecting >50% of hepatic parenchyma) was evaluated by one experienced radiologist (L.G.). The presence of mesenteric desmoplasia was assessed by computed tomography imaging. However, assessment of the extent or degree of desmoplastic reaction was not performed due to the absence of established classification systems.

The aims of this retrospective study were to demonstrate the mean TTRP, as well as identify factors affecting the antiproliferative activity of octreotide LAR in a large cohort of patients with NETs.

Radiological assessment was based on cross-sectional imaging in 4–6 month intervals, using the revised RECIST (version 1.1) criteria (Eisenhauer *et al*, 2009). Many variables were assessed as potential predictive factors of response to treatment with octreotide LAR: age, sex, treatment indication, location of primary tumour, extent of liver involvement, extra-hepatic metastases (bone, peritoneum, mesentery), presence of carcinoid heart disease and mesenteric desmoplasia, tumour grade, functional status (functional or non-functional), resection of primary tumour and baseline CgA level.

**Statistical analysis.** Non-parametric Kaplan–Meier techniques were used to evaluate times to radiological progression, including the median and associated 95% CI, in strata defined by the various explanatory variables. A semi-parametric Cox regression model was used to perform multivariate analysis on a sample of 152 patients with complete information on all covariates of interest (Collett, 2003). By including fewer covariates, additional multivariate models were fitted to larger patient samples to test the robustness of the findings to potential sample bias.

## RESULTS

**Patient characteristics.** A total of 254 patients were included in this retrospective study. The patients' mean age was 60.5 ± 12.8 years. The male to female ratio was 1.1:1. The location of the primary tumour was in the small bowel in 204 (80%), pancreas in 22 (8.5%), lung in 14 (5.5%), rectum in 7 (2.5%) and unknown in 7 patients (2.5%). The histological grade was G1 in 148 (58%), G2 in 59 (23%), G3 in 1 (0.5%) and not available in 47 patients (18.5%). The study population included 183 patients with functional tumours (72%) (of which 97% were serotonin secreting, 1% glucagonomas, 1.5% gastrinomas and 0.5% insulinomas), 67 with non-functional tumours (26%), whereas data on functional status were not available in 4 patients (2%). The primary tumour had been resected before commencement of octreotide LAR in 117 (46%) patients. Indications for commencement of octreotide LAR included functional symptoms in 57%, radiological progression in 10%, a combination of functional symptoms and radiological progression in 3%, whereas 18.5% of patients were asymptomatic with stable disease and started treatment on the basis of data from the PROMID trial (CLARINET trial data were not available during the period covered in this retrospective cohort study). The duration of stable disease before initiation of SSA therapy in this group of patients was at least 3 months. A total of 8% of patients were commenced on octreotide LAR due to a combination of functional symptoms and stable disease (on the basis of data from the PROMID trial) and the indication was not clearly recorded in 3.5% of cases.

A summary of patient baseline characteristics is provided in Table 1.

**Partial (objective) response, TTRP and univariate analysis of predictive factors of tumour control during treatment with octreotide LAR.** Partial (objective) response was noted in 13 patients (5%). For all patients the median and mean TTRP were 37 months (95% CI: 32–52 months) and 51 months (95% CI: 45–57 months), respectively (Figure 1).

The univariate analysis demonstrated that liver and skeletal metastases, G2 tumours and baseline serum CgA levels more than 10 times the upper limit of normal were predictive factors of a shorter TTRP, whereas male sex was associated with a statistically significantly longer TTRP.

Pancreatic and rectal primary tumours demonstrated a trend towards shorter TTRP and tumours associated with carcinoid heart disease demonstrated a trend towards longer TTRP, but both associations did not reach the level of statistical significance.

In contrast, age, treatment indication, peritoneal or mesenteric metastases, functional status, presence of mesenteric desmoplasia and resection of primary tumour were not found to be predictive factors affecting response to treatment.

The results of the univariate analysis are shown in Table 2.

**Multivariate analysis of predictive factors of tumour control during treatment with octreotide LAR.** The multivariate analysis demonstrated that G2 tumours, liver metastases and pancreatic primary tumours were predictors of a shorter TTRP. In contrast, male sex and presence of carcinoid heart disease were predictors of a longer TTRP. In addition, initiation of treatment in asymptomatic patients with stable disease was predictive of a better response to octreotide LAR.

Table 1. Patient baseline characteristics	
N = 254	
<b>Sex</b>	
Male	134
Female	120
<b>Indication for treatment</b>	
Functional symptoms	145
Functional symptoms + progression	8
Functional symptoms + PROMID data	21
Progression	24
PROMID data	47
Unknown	9
<b>Location of primary</b>	
Lung	14
Pancreas	22
Rectum	7
Small bowel	204
Unknown	7
<b>Grade</b>	
Low	148
Intermediate	59
High	1
Unknown	47
<b>Functional status</b>	
Functional	183
Non-functional	67
Unknown	4
<b>Carcinoid heart disease</b>	
Yes	24
No	229
Unknown	1
<b>Desmoplasia</b>	
Yes	67
No	185
Unknown	2
<b>Chromogranin A</b>	
Normal	29
Up to 10 times higher than upper limit of normal	98
> 10 times higher than upper limit of normal	35
Unknown	92
<b>Primary tumour resection</b>	
Yes	117
No	134
Unknown	3

Abbreviation: PROMID = prospective phase III trial.

Age, presence of skeletal, peritoneal and mesenteric metastases, functional status, tumour resection and presence of mesenteric desmoplasia were not found to be predictive of tumour response to therapy.

The results of the multivariate analysis are shown in Table 3.

Two additional multivariate analysis models including fewer covariates were fitted to larger patient samples with complete data, in order to assess the validity of these findings given the potential risk of sampling bias (Supplementary Tables 1 and 2).

**TTRP stratified by factors predictive of response to treatment with octreotide LAR.** The following factors were identified by multivariate analysis as predictive of a favourable or unfavourable response to treatment with octreotide LAR and the TTRP stratified by each of these factors was calculated separately:

*Tumour grade.* The median TTRP was 45 months (95% CI: 33–72 months) for patients with G1 tumours and 21 months (95% CI: 15–37 months) for patients with G2 tumours (Figure 2).

*Liver involvement.* The median TTRP was 105 months (95% CI: 36, NA) for patients without liver metastases, 37 months (95% CI: 26–79 months) for patients with volume of liver metastases < 25%, 23 months (95% CI: 13, NA) for patients with volume of liver metastases 25–50% and 33 months (95% CI: 20, NA) for patients with volume of liver metastases > 50% (Figure 2).

*Location of primary tumour.* The median TTRP was 20 months (95% CI: 12–79 months) for patients with a pancreatic primary tumour, 43 months (95% CI: 32–64 months) for patients with a small bowel primary, 4 months (95% CI: 11, NA) for patients with a lung primary and 8 months (95% CI: 4, NA) for those with a rectal primary (Figure 2).

*Treatment indication.* The median TTRP was 53 months (95% CI: 28, NA) for asymptomatic patients with stable disease. The median TTRP was 32 months (95% CI: 27–51 months) for patients whose indication was functional symptoms and 50 months (95% CI: 35, NA) for patients whose indication was radiological progression. The median TTRP was 43 months (95% CI: 21, NA) for patients with a combination of functional symptoms and radiological progression and 20 months (95% CI: 19, NA) for




Figure 1. Kaplan–Meier estimate of the survival function for the time to tumour progression for all 254 patients. The crosses indicate right-censored data whereby patients' tumours were stable at the last time of contact before being lost to follow-up. The median time to tumour progression is 37 months (95% CI: 32–52 months), given by the time at which the Kaplan–Meier estimate of the survival function is 0.5. The mean time to tumour progression is 51 months (95% CI: 45–57 months), calculated using a restricted upper time limit of 120 months.

**Table 2. Descriptive univariate analysis of explanatory factors predicting time to tumour progression for patients treated with octreotide**

Explanatory factor	Levels	Sample size	Progression events	KM median months to progression (95% CI)	Cox regression	
					Coefficient	P-values
Age	≤60	115	64	43 (32, 71)	NA	NA
	>60	139	66	33 (28, 65)	0.04	0.84
Sex	Female	120	72	32 (23, 45)	NA	NA
	Male	134	58	49 (36, 96)	-0.42	0.02
Reason for treatment	Functional	145	83	32 (27, 51)	NA	NA
	Functional & progression	8	4	43 (21, NA)	-0.23	0.65
	Functional & PROMID	21	10	30 (19, NA)	0.17	0.62
	Progression	24	11	50 (35, NA)	-0.56	0.10
	PROMID	47	17	53 (28, NA)	-0.25	0.35
Primary tumour	Small bowel	204	101	43 (32, 64)	NA	NA
	Pancreas	22	17	20 (12, 79)	0.52	0.058
	Lung	14	6	NA (11, NA)	0.37	0.38
	Rectum	7	4	8 (4, NA)	1.4	0.062
Volume liver metastases	0	51	16	105 (36, NA)	NA	NA
	1	79	39	37 (26, 79)	0.63	0.036
	2	37	20	23 (13, NA)	0.88	0.0089
	3	26	15	33 (20, NA)	0.87	0.016
Skeletal metastases	No	221	110	40 (33, 60)	NA	NA
	Yes	32	19	20 (16, NA)	0.51	0.043
Peritoneal metastases	No	176	87	46 (30, 71)	NA	NA
	Yes	78	43	33 (30, 45)	0.28	0.14
Mesenteric metastases	No	209	109	37 (31, 64)	NA	NA
	Yes	43	19	32 (22, NA)	-0.043	0.86
Carcinoid heart	No	229	119	36 (30, 51)	NA	NA
	Yes	24	10	72 (33, NA)	-0.58	0.082
Grade	1 (low)	148	71	45 (33, 72)	NA	NA
	2 (intermediate)	59	37	21 (15, 37)	0.73	<0.001
Functional	No	183	92	45 (31, 65)	NA	NA
	Yes	67	34	36 (26, NA)	-0.027	0.89
Desmoplasia	No	185	96	36 (30, 64)	NA	NA
	Yes	67	32	36 (30, NA)	-0.14	0.5
Tumour resected	No	134	72	36 (30, NA)	NA	NA
	Yes	117	55	43 (30, 78)	-0.17	0.36
Chromogranin A	<60 (normal)	29	10	93 (35, NA)	NA	NA
	61-600 (elevated)	98	42	53 (19, 79)	0.59	0.097
	>600 (very elevated)	35	22	30 (19, NA)	1.15	0.0029

Abbreviations: CI = confidence interval; KM = Kaplan-Meier; NA = not available. For the Cox regression results: (a) coefficients are negative for a slower time to tumour progression (a better response) and vice versa, and (b) baseline factor levels are not associated with a coefficient or P-value and are denoted NA. Some upper confidence limits for the KM estimate of the median time to progression could not be estimated from the available data and are denoted NA. The median time to progression of bronchial primary tumours could also not be estimated from the available data.

patients, whose indications were both functional symptoms and stable disease (initiated on SSA therapy on the basis of evidence from the PROMID trial; Figure 2).

**Carcinoid heart disease.** The median TTRP was 36 months (95% CI: 30-51 months) for patients without carcinoid heart disease and 72 months (95% CI: 33, NA) for patients with carcinoid heart disease (Figure 2).

A subsequent analysis of electronic records of patients with carcinoid heart disease revealed that the majority of patients had mild carcinoid heart disease with NYHA class I (54%) or II (37.5%). Most of these patients (92%) also had N-terminal pro b-type natriuretic peptide (NT pro-BNP) values of  $<400 \text{ pg ml}^{-1}$ , which has been proposed as a cut-off value predictive of a diagnosis of chronic heart failure (Al-Mohammad *et al*, 2010).

**Sex.** The median TTRP was 32 months (95% CI: 23-45 months) for female and 49 months (95% CI: 36-96 months) for male patients (Figure 2).

## DISCUSSION

**Partial (objective) response and TTRP.** The present study demonstrated that in a large cohort of patients with NETs on octreotide LAR the partial (objective) response rate was 5%. This is in keeping with the results of other prospective and retrospective studies, which have shown partial (objective) response rates of 0-10% (Saltz *et al*, 1993; Arnold *et al*, 1996; di Bartolomeo *et al*, 1996; Eriksson *et al*, 1997; Wymenga *et al*, 1999; Ducreux *et al*, 2000; Aparicio *et al*, 2001; Shojamanesh *et al*, 2002; Faiss *et al*, 2003; Rinke *et al*, 2009; Toumpanakis *et al*, 2009; Martin-Richard *et al*, 2013; Palazzo *et al*, 2013; Ramundo *et al*, 2014; Supplementary Table 3).

However, in our study the TTRP was 37 months, which is longer than that reported in most other studies (Arnold *et al*, 1996; Shojamanesh *et al*, 2002; Butturini *et al*, 2006; Rinke *et al*, 2009; Toumpanakis *et al*, 2009; Palazzo *et al*, 2013; Martin-Richard *et al*, 2013; Caplin *et al*, 2014; Supplementary Table 3). It is possible that differences in the baseline patient and tumour characteristics among various studies may account for this variation in TTRP.



**Table 3. Coefficients, s.e. and P-values for the maximum Cox regression (proportional hazards) model**

Explanatory factor	Levels	Coefficient	s.e.	P-values
Age	≤60	NA	NA	NA
	>60	0.33	1.4	0.26
Sex	Female	NA	NA	NA
	Male	-0.46	0.27	0.010
Skeletal metastases	No	NA	NA	NA
	Yes	-0.027	0.43	0.95
Peritoneal metastases	No	NA	NA	NA
	Yes	-0.38	0.32	0.24
Mesenteric metastases	No	NA	NA	NA
	Yes	0.22	0.36	0.54
Carcinoid heart disease	No	NA	NA	NA
	Yes	-1.5	0.63	0.019*
Functional	No	NA	NA	NA
	Yes	-0.0011	0.33	0.99
Desmoplasia	No	NA	NA	NA
	Yes	-0.022	0.33	0.95
Tumour resected	No	NA	NA	NA
	Yes	-0.057	0.28	0.84
Treatment indication	Functional	NA	NA	NA
	Functional and progression	-1.87	1.2	0.11
	Functional and PROMID	-0.29	0.43	0.51
	Progression PROMID	-0.99	0.51	0.051
Primary tumour	Small bowel	NA	NA	NA
	Pancreas	1.4	0.41	0.001**
	Lung	-1.5	1.0	0.15
	Rectum	0.88	1.1	0.43
Volume of liver metastases	0	NA	NA	NA
	1	1.1	0.41	0.006**
	2	1.2	0.47	0.013*
	3	1.2	0.49	0.016*
Tumour grade	Low	NA	NA	NA
	Intermediate	1.0	0.29	0.001*
	High	NA	NA	NA

Abbreviations: NA = not available; PROMID = prospective phase III trial. Coefficients are negative for a slower time to tumour progression (a better response) and vice versa. Baseline factor levels are not associated with a coefficient or P-value and are denoted NA. Sample size is 152 (254 total). Likelihood-ratio statistic = 55 on 21 degrees of freedom (comparing with the null intercept-only model),  $P < 0.001$ . \* $P < 0.05$ ; \*\* $P < 0.01$ .

**Predictive factors of tumour response.** There is only a small number of studies that have identified predictors of tumour response to SSA therapy and these are summarised in Supplementary Table 4.

Our study is the largest retrospective study in the literature aiming to determine predictive factors of radiological response to SSA therapy. Its large sample size has allowed the analysis of multiple variables as potential predictive factors. Such analysis was not feasible in previous studies due to the small study samples. Some of our study findings are in keeping with those of previously published studies, although some differences are also present.

In our study, the multivariate analysis revealed that G2 tumours were less likely to respond to octreotide LAR. Similarly, a small prospective study demonstrated that lower proliferation index (Ki67) predicted superior tumour growth control, although this association did not quite reach the level of statistical significance, perhaps due to the small sample size (Martin-Richard *et al*, 2013). Another small prospective study which included advanced, well-differentiated, non-functional pancreatic NETs concluded that

tumour progression correlated with a Ki67  $\geq 5\%$ , weight loss and absence of abdominal pain (Butturini *et al*, 2006).

Our study also showed that liver metastases are predictive of a poor response to treatment. Palazzo *et al* (2013) also found that Ki67  $< 5\%$ , hepatic tumour load  $< 25\%$  and pre-treatment stability were associated with disease stability on lanreotide therapy. The PROMID trial also suggested that the antiproliferative activity of octreotide LAR was more pronounced in patients with a low ( $\leq 10\%$ ) hepatic tumour load and a resected primary tumour (Rinke *et al*, 2009). A previous retrospective study performed in our centre showed that in a subgroup of patients with G1 tumours, bilobar liver metastases at the time of commencement of treatment and plasma CgA levels  $> 1000 \text{ pmol l}^{-1}$  were predictive of radiological progression (Toumpanakis *et al*, 2009). Interestingly, our univariate analysis also showed that CgA levels  $> 10$  times the upper limit of normal were predictive of a poor response, although this could not be confirmed in the multivariate analysis due to missing data in a large number of subjects.

In addition, our multivariate analysis showed that pancreatic tumours were less likely to respond to treatment. A previous prospective study also demonstrated that patients with midgut NETs showed a statistically significant prolonged length of time to tumour progression compared with foregut tumours (most of which were pancreatic), although the study population included not only patients treated with lanreotide, but also patients treated with interferon or a combination of both drugs (Faiss *et al*, 2003).

Moreover, our results demonstrated that asymptomatic patients with stable disease were more likely to respond to treatment. Similarly, other studies have shown that rapidly progressive tumours are less likely to respond to treatment compared with stable or slowly progressive tumours before initiation of SSA (Aparicio *et al*, 2001; Shojamanesh *et al*, 2002; Palazzo *et al*, 2013).

The present study also revealed that male sex and carcinoid heart disease were favourable predictive factors of tumour response. These variables were statistically significant across all multivariate analysis models. This was an unexpected finding, as carcinoid heart disease is associated with poor prognosis. However, an analysis of the electronic case notes of patients with carcinoid heart disease revealed that the vast majority of cases had only mild disease and it is possible that they were perhaps followed-up and treated more aggressively, which resulted in a more favourable outcome.

Finally, primary tumour resection has been identified in other studies as predictive of a better response to SSA therapy (Panzuto *et al*, 2006). In our study, this factor was not found to be significant in any of the multivariate analysis models.

Although many of our study findings are in keeping with those of other studies, some differences are also present. These may be due to differences in predictive factors assessed, heterogeneity of study populations, differences in sample sizes and use of different SSAs amongst various studies. In practical terms, however, decisions regarding initiation of SSA therapy still need to be made on a case-by-case basis, although these may be influenced by the presence of associated predictive factors.

**Limitations and conclusions.** There are several limitations to this study. Because of retrospective data collection the results are potentially subject to interpretation bias and bias because of missing data. In addition, this is a single-centre cohort study in a tertiary and quaternary referral centre which attracts many referrals outside its geographical catchment area. Therefore, the profile of our patients and clinical practices may not be typical of regional centres and the extrapolation of our findings to other populations can be questioned. It is difficult to quantify the degree of potential bias, but the fact that many of our results are in keeping with those of previous studies suggests that this may not be a major area of concern. Furthermore, in our




Figure 2. Kaplan–Meier estimates of the survival function for time to tumour progression in patients with advanced neuroendocrine tumours, stratified by different variables.

study the vast majority of patients had small bowel primary tumours ( $n=204$ ) followed by pancreatic ( $n=22$ ), lung ( $n=14$ ) and rectal primaries ( $n=7$ ). Therefore, our results may be more reliable for patients with small bowel and pancreatic NETs and less robust for other NETs. Finally, the majority of patients with functional tumours were those with carcinoid syndrome as a result of a small bowel primary NET. Only a minority of patients had functional pancreatic tumours, such as insulinoma or glucagonoma. As a result, our findings on the impact of functional status on the antiproliferative activity of SSA therapy mainly reflect the presence or not of carcinoid syndrome.

In conclusion, the current study suggests that the duration of the anti-proliferative effect of octreotide LAR is longer than previously reported. Male sex, carcinoid heart disease and possibly disease stability at the time of commencement of SSA therapy are predictive of a better response, although the vast majority of patients had minor cardiac disturbance and might have been treated and followed-up more aggressively resulting in a more positive outcome. Age, extra-hepatic metastases (other than perhaps skeletal), mesenteric desmoplasia, tumour functional

status and primary tumour resection do not appear to have any effect on treatment. In contrast, liver (and perhaps skeletal) metastases, intermediate grade tumours, pancreatic primary tumours and possibly extremely raised CgA levels may be associated with an unfavourable response.

**CONFLICT OF INTEREST**

MC and CT are on the advisory boards. They received research funding and honoraria for lectures from NOVARTIS and IPSEN. The remaining authors declare no conflict of interest.

**REFERENCES**

Al-Mohammad A, Mant J, Laramée P (2010) Diagnosis and management of adults with chronic heart failure: summary of updated NICE guidance. *BMJ* 341: c4130.

- Aparicio T, Ducreux M, Baudin E, Sabourin JC, De Baere T, Mitry E, Schlumberger M, Rougier P (2001) Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. *Eur J Cancer* **37**(8): 1014–1019.
- Arnold R, Trautmann ME, Creutzfeldt W, Benning R, Benning M, Neuhaus C, Jürgensen R, Stein K, Schäfer H, Bruns C, Dennler HJ (1996) Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. *Gut* **38**(3): 430–438.
- Bosman FT, Carneiro F, Hruban RH, Theise ND (2010) *WHO Classification of Tumours of the Digestive System*. 4th edn. Lyon: IARC.
- Butturini G, Bettini R, Missiaglia E, Mantovani W, Dalai I, Capelli P, Ferdeghini M, Pederzoli P, Scarpa A, Falconi M (2006) Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma. *Endocr Relat Cancer* **13**(4): 1213–1221.
- Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Blumberg J, Ruzsniwski P. CLARINET Investigators (2014) Lanreotide in metastatic enteropancreatic neuroendocrine tumors. *N Engl J Med* **371**(3): 224–233.
- Collett D (2003) *Modelling Survival Data in Medical Research*. Chapman & Hall: London.
- di Bartolomeo M, Bajetta E, Buzzoni R, Mariani L, Carnaghi C, Somma L, Zilembo N, di Leo A (1996) Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. *Cancer* **77**(2): 402–408.
- Ducreux M, Ruzsniwski P, Chayvialle JA, Blumberg J, Cloarec D, Michel H, Raymond JM, Dupas JL, Gouerou H, Jian R, Genestin E, Hammel P, Rougier P (2000) The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. *Am J Gastroenterol* **95**(11): 3276–3281.
- Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer* **45**(2): 228–247.
- Eriksson B, Renstrup J, Imam H, Oberg K (1997) High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects. *Ann Oncol* **8**(10): 1041–1044.
- Faiss S, Pape UF, Böhmig M, Dörffel Y, Mansmann U, Golder W, Riecken EO, Wiedenmann B (2003) Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferonalfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors—the International Lanreotide and Interferon Alfa Study Group. *J Clin Oncol* **21**(14): 2689–2696.
- Martin-Richard M, Massuti B, Pineda E, Alonso V, Marmol M, Castellano D, Fonseca E, Galán A, Llanos M, Sala MA, Pericay C, Rivera F, Sastre J, Segura A, Quindós M, Maisonobe P. TTD (Tumores del Tracto Digestivo) Study Group (2013) Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study. *BMC Cancer* **13**: 427.
- Palazzo M, Lombard-Bohas C, Cadiot G, Matysiak-Budnik T, Rebours V, Vullierme MP, Couvelard A, Hentic O, Ruzsniwski P (2013) Ki67 proliferation index, hepatic tumor load, and pretreatment tumor growth predict the antitumoral efficacy of lanreotide in patients with malignant digestive neuroendocrine tumors. *Eur J Gastroenterol Hepatol* **25**(2): 232–238.
- Panzuto F, Di Fonzo M, Iannicelli E, Sciuto R, Maini CL, Capurso G, Milione M, Cattaruzza MS, Falconi M, David V, Ziparo V, Pederzoli P, Bordi C, Delle Fave G (2006) Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. *Ann Oncol* **17**(3): 461–466.
- Ramage J, Ahmed A, Ardill J, Bax N, Breen D, Caplin M, Corrie P, Davar J, Davies A, Lewington V, Meyer T, Newell-Price J, Poston G, Reed N, Rockall A, Steward W, Thakker RV, Toubanakis C, Valle J, Verbeke C, Grossman AB. UK and Ireland Neuroendocrine Tumour Society (2012) Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). *Gut* **61**(1): 6–32.
- Ramundo V, Del Prete M, Marotta V, Marciello F, Camera L, Napolitano V, De Luca L, Circelli L, Colantuoni V, Di Sarno A, Carratù AC, de Luca di Roseto C, Colao A, Faggiano A. Multidisciplinary Group for Neuroendocrine Tumors of Naples (2014) Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours. *Clin Endocrinol (Oxf)* **80**(6): 850–855.
- Rindi G, Klöppel G, Couvelard A, Komminoth P, Körner M, Lopes J, McNicol A, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B (2007) TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. *Virchows Arch* **451**: 757–762.
- Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, Harder J, Arnold C, Gress T, Arnold R. PROMID Study Group (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. *J Clin Oncol* **27**(28): 4656–4663.
- Saltz L, Trochanowski B, Buckley M, Heffernan B, Niedzwiecki D, Tao Y, Kelsen D (1993) Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. *Cancer* **72**(1): 244–248.
- Shojamanesh H, Gibril F, Louie A, Ojeaburu JV, Bashir S, Abou-Saif A, Jensen RT (2002) Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. *Cancer* **94**(2): 331–343.
- Toumpanakis C, Caplin M (2013) Update on the role of somatostatin analogs for the treatment of patients with gastroenteropancreatic neuroendocrine tumors. *Semin Oncol* **40**(1): 56–68.
- Toumpanakis C, Garland J, Marelli L, Srirajskanthan R, Soh J, Davies P, Buscombe J, Caplin ME (2009) Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR. *Aliment Pharmacol Ther* **30**(7): 733–740.
- Wymenga AN, Eriksson B, Salmela PI, Jacobsen MB, Van Cutsem EJ, Fiasse RH, Välimäki MJ, Renstrup J, de Vries EG, Oberg KE (1999) Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. *J Clin Oncol* **17**(4): 1111.

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License.

Supplementary Information accompanies this paper on British Journal of Cancer website (<http://www.nature.com/bjc>)